A Phase 1 interventional study of LY3090106 and Placebo in Sjögren's Syndrome, sponsored by Eli Lilly and Company. Completed at 7 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-12-11.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.
Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 51st largest by enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2015, is one of 15 in phase 1, and was the 41st registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
Vor Biopharma · Sites in United States, Georgia
Ages 18–75
National Institute of Dental and Craniofacial Research (NIDCR) · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 36 · Phase 3 14 · Phase 4 3
First in 1984; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 57 across the 76 interventional studies, 220 across the 35 observational. Of the 76 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 111 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 1 study filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Sjogren's Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
| NCT07277257Center For SightEvaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome | 2026-12-31 |
| NCT03276923Duke UniversityMaternal Autoimmune Disease Research Alliance (MADRA) Registry | 2027-01-01 |
| NCT07732582Tufts UniversitySjogren's Mini-Pill Oral and Gut Microbiome Study | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 111 studies in Sjogren's Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sjögren's Syndrome (SS). The study will also evaluate how much of the study drug gets into the blood stream and how long it takes the body to remove it.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Are currently enrolled in a clinical trial involving an product or off-label use of a drug, are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study, or have received:
Have synthetic disease-modifying anti-rheumatic drug (DMARD) or use as follows:
Have had treatment with biologic DMARDs as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY3090106 given subcutaneously (SC) in escalating dose cohorts once every 2 or 4 weeks for 16 weeks.
Drug: LY3090106
Placebo given subcutaneously (SC) once every 2 or 4 weeks for 16 weeks.
Drug: Placebo
Administered SC
Administered SC
Number of Participants with One or More Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through Study Completion (Day 197)
Pharmacokinetics: Maximum Concentration (Cmax) of LY3090106
Time frame: Baseline through Day 197
Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3090106
Time frame: Baseline through Day 197
Ran from Dec 2015 to primary completion in Sep 2018, 32 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tibulizumab